Antje Schaefer
@AntjeSchaeferZ
Followers
360
Following
1K
Media
16
Statuses
376
Assistant Prof @MCWPharmTox @MCWCancerCenter I gastric & pancreatic cancer, RHO & RAS GTPases I @UNC_Lineberger @UNC_PHCO 🇺🇸 & @mpimoph 🇩🇪 alumni
Milwaukee, WI
Joined July 2018
🚨 New article alert! 🚨 Take a look at our last article "The pro-oncogenic noncanonical activity of a RAS•GTP:RanGAP1 complex facilitates nuclear protein export is live". @NCIDrDougLowy @theNCI Read more here:
nature.com
Nature Cancer - Tripathi et al. identify a noncanonical RAS•GTP activity that increases XPO1-dependent export of nuclear proteins into the cytoplasm. This depends on a RAS–RanGAP1...
0
2
7
First @MCWCancerCenter Retreat as a #NewPI in the books - great #CancerResearch & scientific discussions! #AcademicTwitter
We have a full garage at the @harleydavidson museum for our annual Scientific Retreat! Our researchers are pumped to listen, learn, and collaborate on ways to advance discoveries and end #cancer for good.🧪🧬
1
0
10
Join us on Tuesday, November 12, 2024 at 4:00 PM CT to learn more about MCW’s various biomedical PhD programs! #academictwitter #phd #biomed #MCWKnowledge @mcwgradschool We also have Interdisciplinary and Neuroscience programs. Register here: https://t.co/fTBWJKg3Hz
2
7
9
Great to see the preprint from @owen_sansom published in @CR_AACR KRAS Loss of Heterozygosity Promotes MAPK-Dependent #PancreaticCancer Initiation and Induces Therapeutic Sensitivity to MEK Inhibition https://t.co/IEmnnzE3pe In the KRAS inhibitor era, these findings on the wild
1
20
71
I am not going to be in Chicago for #sfn2024, but several Mantsch lab team members will. If you are going, check out these posters from Dani, Mary, Beliz and David! @McwPharmTox @NeuroscienceMCW
0
3
21
Interested in working in gastric & pancreatic #cancer biology and cancer therapy resistance in a collaborative lab in Milwaukee? Our lab in is looking for a Research Technician! Happy to answer any questions! More info here: https://t.co/zSw19lBubT… or
0
1
4
We are excited to have @theNCI blog feature two of our articles exploring how combining chemotherapy with a KRAS inhibitor decreases tumor growth and metastasis in pancreatic cancer better than either treatment alone. https://t.co/RyJakvlIyz  Read the studies here 🧵
cancer.gov
Adding chemotherapy to the experimental KRAS inhibitor MRTX1133 greatly reduced tumor growth and spread in mice compared with either treatment alone.
1
7
19
Analyzing cell differentiation in organoids this past week & really enjoying watching these minicolons grow #timelapse #microscopy
3
11
135
Thrilled to see our study where we investigated resistance to mutant-specific KRAS inhibition in PDAC across patients specimens and multiple preclinical models. Grateful for the support from our academic and industry partners!
@CD_AACR In their paper, @Julien__Dilly, Megan Hoffman, @laleh_abbassi, Ziyue Li, @FraHeaven
@SriRaghavanMD @jonathan_nowak @peterswinter Stephanie Dougan @andrewaguirremd et al identify mechanisms of resistance to KRAS inhibition in pancreatic cancer https://t.co/zhfPXcuP2v
@DanaFarber
1
7
24
Intriguing talk by @AntjeSchaeferZ about RHOA-driven gastric cancer. @FASEBorg #RGTPSRC Excited about future extensions into KRAS-mutant #pancreaticcancer. @MedicalCollege
3
5
27
Exciting presentations today from The Philips lab at the FASEB Small GTPases conference! Amazing keynote lecture by Mark this morning, and flash poster presentation by Mercedes! Go visit her at poster 24 to find out more about KRASA novel interactors! #RGTPSRC
1
1
8
Excellent talk from @castel_pau describing RIT1 function in cancer and possible therapeutic vulnerabilities. #RGTPSRC @FASEBorg
1
2
7
Exciting talk from @AndrewMWaters about the distinct resistance mechanisms of different #RAS inhibitors in #pancreaticcancer @FASEBorg Function & Regulation of Small #GTPases meeting. Can’t wait what his lab @uofcincycancer will achieve in the coming years! #RGTPSRC
2
8
38
Excited to be part of this study in @ScienceMagazine, looking into the details of the growth & therapy resistance of KRAS mutant cancers like #pancreaticcancer ; with an interesting role of RHO #GTPases!
0
1
11
Great bench-to-the-clinic example to improve diffuse #gastricCancer therapies
Our investigator-initiated trial targeting the FAK and MAPK pathways with defactinib and avutometinib for patients with diffuse gastric cancer after progression on first-line therapy is now open at Columbia! https://t.co/xwMeUlFYZe
0
0
6
New review from our group @cincysurgery @UCincyMedicine comparing and contrasting mutant-selective-, pan-KRAS, and RAS(MULTI)ON-selective RAS inhibitors in pancreatic cancer with standards of care: @SzuAunLongMD @SyedAAhmad5 @ambermamparo @grace_goodhart
https://t.co/kxZyKA0yuV
2
9
38
We have two open positions in my lab! We are looking for a #postdoc and a #technician to contribute to our mission to define deregulated splicing events driving cancer progression and metastasis. Come science with us! Apply right now! @MoffittNews
3
13
17
Forever grateful for the tremendous support of mentors, colleagues in @derlabunc @UNC_PHCO @UNC_Lineberger , friends & family!Special thanks to Channing Der, Adrienne Cox @BassLab_CU @Coronin @AndrewMWaters @bryant_kl @Dr_Kevin_Pruitt and many more. 3/3
1
0
4
We will study #gastricCancer and #pancreaticCancer growth and therapy resistance, combining structural biochemistry, organoid models, fluorescence microscopy & proteomics. Stay tuned if interested in joining! 2/3 #newPI
2
1
2